Jerry Isaacson has joined Roth Capital Partners as a managing director and senior research analyst covering biotechnology and emerging therapeutics.
Dr. Isaacson has a broad range of experience covering companies in many different disease areas as well as medical devices and diagnostics. He is particularly focused on anti-infectives, gene therapy, and oncology.
Prior to joining Roth, he spent seven years leading the research group of LifeSci Capital, where he built the research team from the ground up and initiated coverage on more than 100 companies.
In a statement, Jeff Martin, director of research for Roth, said Dr. Isaacson’s strong academic background in organic chemistry combined with his extensive experience in covering biotechnology companies would serve Roth’s clients well.
Dr. Isaacson said the recent emergence of new treatment modalities as well as genomic and diagnostic tools makes this a very exciting time in the biotechnology arena for patients, physicians, drug developers, and investors.
Byron Roth, CEO of Roth Capital Partners, added that “Jerry’s expertise in biotechnology will enhance our ability to continue to build upon our over ten-year track record of success in assisting both companies and investors in the healthcare sector.”
